|
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
26 gevonden resultaten
| nr | titel | auteur | tijdschrift | jaar | jaarg. | afl. | pagina('s) | type |
| 1 | An international perspective on antimicrobial resistance |
Wiedemann, Bernd |
1995 |
99 | 6S1 |
p. 19s-20s nvt p. |
artikel |
|
| 2 | Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides |
Kobayashi, Hiroyuki |
1995 |
99 | 6S1 |
p. 26s-30s nvt p. |
artikel |
|
| 3 | Clinical drug resistance: The role of factors other than P-glycoprotein |
Kaye, Stanley B. |
1995 |
99 | 6S1 |
p. 40s-44s nvt p. |
artikel |
|
| 4 | Combination of BRMs with chemotherapy |
Tursz, Thomas |
1995 |
99 | 6S1 |
p. 56s-58s nvt p. |
artikel |
|
| 5 | Do monoclonal antibodies and anticytokines still have a future in infectious diseases? |
Cohen, Jonathan |
1995 |
99 | 6S1 |
p. 45s-52s nvt p. |
artikel |
|
| 6 | Funding, education, and training in the context of industry-academia relations |
Mak, Tak W. |
1995 |
99 | 6S1 |
p. 84s-86s nvt p. |
artikel |
|
| 7 | Immunopathogenic mechanisms of human immunodeficiency virus disease: Implications for therapy |
Fauci, Anthony |
1995 |
99 | 6S1 |
p. 59s-60s nvt p. |
artikel |
|
| 8 | Impact of molecular biology on antibiotic susceptibility: Testing and therapy |
Courvalin, Patrice |
1995 |
99 | 6S1 |
p. 21s-25s nvt p. |
artikel |
|
| 9 | Introduction: A turning point |
Bergeron, Michel G. |
1995 |
99 | 6S1 |
p. 1s-3s nvt p. |
artikel |
|
| 10 | Introduction to discussion |
Tannock, Ian |
1995 |
99 | 6S1 |
p. 68s-69s nvt p. |
artikel |
|
| 11 | Introduction: Vision of the future |
Bergeron, Michel G. |
1995 |
99 | 6S1 |
p. 79s-80s nvt p. |
artikel |
|
| 12 | Overview: Therapeutic monoclonal antibodies and anticytokines in infectious diseases |
Young, Lowell S. |
1995 |
99 | 6S1 |
p. 52s-53s nvt p. |
artikel |
|
| 13 | Pasteur's legacy |
Montagnier, Luc |
1995 |
99 | 6S1 |
p. 4s-5s nvt p. |
artikel |
|
| 14 | Past, present, and future of antimicrobial agents |
Moellering Jr., Robert C. |
1995 |
99 | 6S1 |
p. 11s-18s nvt p. |
artikel |
|
| 15 | P-glycoprotein: Its role in drug resistance |
Ling, Victor |
1995 |
99 | 6S1 |
p. 31s-34s nvt p. |
artikel |
|
| 16 | Phorbol ester and okadaic acid-resistant cells: The crossroads of signal transduction and drug resistance |
Saijo, Nagahiro |
1995 |
99 | 6S1 |
p. 35s-39s nvt p. |
artikel |
|
| 17 | Present status of biological response modifiers in cancer |
Parkinson, David R. |
1995 |
99 | 6S1 |
p. 54s-56s nvt p. |
artikel |
|
| 18 | Promoting synergism in an era of change |
Wittes, Robert E. |
1995 |
99 | 6S1 |
p. 87s-90s nvt p. |
artikel |
|
| 19 | Summary of discussion |
Tannock, Ian |
1995 |
99 | 6S1 |
p. 77s-78s nvt p. |
artikel |
|
| 20 | Targeting fungi: A challenge |
Meunier, Francoise |
1995 |
99 | 6S1 |
p. 60s-67s nvt p. |
artikel |
|
| 21 | The future for partnerships between universities and industry |
Richmond, Mark H. |
1995 |
99 | 6S1 |
p. 81s-83s nvt p. |
artikel |
|
| 22 | The treatment of AIDS and cancer in the third millennium |
Gallo, Robert C. |
1995 |
99 | 6S1 |
p. 6s-10s nvt p. |
artikel |
|
| 23 | University-industry collaboration |
Miller jr., Robert C. |
1995 |
99 | 6S1 |
p. 90s-92s nvt p. |
artikel |
|
| 24 | Vision and reality of industry-academia interaction in Canada |
Friesen, Henry |
1995 |
99 | 6S1 |
p. 80s-81s nvt p. |
artikel |
|
| 25 | Will increases in dose intensity improve outcome: Con |
Souhami, Robert L. |
1995 |
99 | 6S1 |
p. 71s-76s nvt p. |
artikel |
|
| 26 | Will increases in dose intensity improve outcome: Pro |
Hryniuk, William |
1995 |
99 | 6S1 |
p. 69s-70s nvt p. |
artikel |
26 gevonden resultaten